Építés alatt – nem éles oldal
Belépés
Befejeződött2. fázis

Efficacy and Safety of Acyclovir-penciclovir Cream Versus an Abreva in the Suppression of Herpes Simplex Virus Eruptions

A legfontosabb adatok

Ki végzi
University of Utah
Hol
Murray (Egyesült Államok)A helyszín megnézése
Azonosító
Állapot
Befejeződött
Fázis
2. fázis
Résztvevők
58 fő vett részt
Kezdés
2024. aug. 19.
Befejezés
2025. nov. 30.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
A vizsgált kezelések
  • acyclovir-penciclovir cream
  • Abreva
A regiszteradat frissítve
2026. október 27.

Ki vehet részt

Életkor
18 év – 80 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 23 feltétel megnézéseKevesebb

Ki vehet részt

  • Understands the requirements of the study and provides written informed consent prior to undergoing any study-related procedures
  • Subject is a male or female between the ages of 18-80 years old, inclusive
  • Fitzpatrick skin type II or III
  • History of at least one year of herpes labialis induced by UV exposure
  • Able to recall exact location of most common or most recent outbreak
  • History of at least 50% of cold sore outbreaks occurring with UV (sun) exposure
  • At least 1 HSV-1 outbreak within the past 12 months
  • Experiences prodromal symptoms before HSV-1 outbreaks
  • Subject is willing and able to comply with protocol-specified dosing, visits to the clinic and tracking of pain

Ki nem vehet részt

  • Outbreak <2 weeks prior to enrollment
  • On any systemic or topical steroid, immune suppressant or chemotherapeutic agent within the past 14 days
  • Use of tanning beds, history of sunburn, or beach vacation <2 weeks prior to enrollment
  • Current immunosuppressed state due to underlying disease (i.e. HIV infection) concomitant treatment (i.e. chemotherapy)
  • Alcohol or drug abuse
  • History of herpes simplex vaccine
  • History of photosensitivity, lupus erythematosus, or current use of a highly photosensitizing medication in the opinion of the investigator
  • Current upper respiratory tract infection or any active illness that could trigger cold sores or affect overall health of the patient or the assessment of the study agent
  • Abnormal skin conditions in the area of the recurrent HSV1 outbreaks
  • On antiviral suppression within the past 30 days
  • Requires more than acetaminophen for pain from recurrent HSV outbreaks
  • Pregnant or intending to become pregnant during the study
  • Enrolled in another clinical trial within the past 30 days
  • On any analgesics or NSAIDs that cannot be stopped during the study

Helyszínek itt: Egyesült Államok

  • University of Utah Midvalley DermatologyMurray, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

This will be a randomized, efficacy assessor-blinded, parallel group, pilot study of up to 40 subjects with documented herpes labialis. Patients will be treated with the study drug, acyclovir-penciclovir cream, or the active comparator of Abreva.

A teljes eredeti leírásKevesebb

Potential subjects will be assessed during a screening visit that must take place no greater than 2 weeks prior to the Day 1 (Baseline) visit. During the screening period, subjects that meet all other entry criteria will undergo Ultraviolet susceptibility testing to determine the subject's individual minimal erythema dose (MED). Ultraviolet susceptibility testing takes place over two days with exposure to Ultraviolet light on specified regions on the subject's back followed by an assessment of the exposed areas 24 hours later to identify the MED. Subjects who have a measurable MED will be allowed to enroll in the study. Each subject will be randomly assigned in a 1:1 ratio to receive either acyclovir-penciclovir cream or Comparator (Abreva).

Patients who express a cold sore will track the lesion with a diary card to rate their pain levels, and any unusual symptoms at Day 1, Day 3, Day 5, Day 7, and Day 10. Patients may also take photographs of the lesion throughout the study.

A vizsgálat 2 csoportja

  • Study Drug (acyclovir-penciclovir cream)A vizsgált kezelés

    Patients will treat herpes simplex eruption with active study drug.

    Kezelés: acyclovir-penciclovir cream

  • Active Comparator (Abreva)Már használt kezelés, összehasonlításként

    Patients will treat herpes simplex eruption with Abreva.

    Kezelés: Abreva

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Randomized, Parallel Group, Pilot Study to Assess Efficacy and Safety of Acyclovir-penciclovir Cream Versus an Active Comparator (Abreva) in the Suppression of Herpes Simplex Virus Eruptions in Subjects With a History of Herpes Labialis
A regiszteradat frissítve
2026. október 27.